Intrexon | XON - Capital Social Ordinario





Capital Social Ordinario Cambio Fecha
Agenus USD 35.32M 2.51M 2025-12
Alaunos Therapeutics USD 2.21M 131K 2025-09
Amgen USD 539M 1000K 2025-12
Anika Therapeutics USD 13.89M 532K 2025-12
Arrowhead Research USD 135.7M 2.44M 2025-09
AstraZeneca USD 1.55B 206K 2025-12
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Gilead Sciences USD 1.24B 1000K 2025-12
GlaxoSmithKline GBP 4.08B 49.43M 2025-12
Heron Therapeutics USD 188.31M 4.99M 2025-12
Incyte USD 198.46M 2.33M 2025-12
Intrexon USD 0 0 2024-06
Karyopharm Therapeutics USD 13K 0 2024-09
Ligand Pharmaceuticals USD 19.66M 19.64M 2025-09
MacroGenics USD 63.32M 60K 2025-12
MannKind USD 307.83M 806K 2025-12
Merck USD 2.49B 15.79M 2025-09
Novartis USD 1.91B 10.64M 2025-12
Rigel Pharmaceuticals USD 17K 158K 2024-06
Roche Holding CHF 795.62M 699.54K 2025-12
Thermo Fisher Scientific USD 375.71M 1.9M 2025-12
Veracyte USD 79.05M 377K 2025-12
Xencor USD 71.87M 529K 2025-12